The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive epithelial ovarian cancer (EOC).
Kenneth H. Kim
No relevant relationships to disclose
Danijela Jelovac
No relevant relationships to disclose
Deborah Kay Armstrong
Consultant or Advisory Role - Genentech; Morphotek
Research Funding - Eisai (I); Exelixis (I)
Susan Weil
Employment or Leadership Position - Morphotek
Martin Phillips
Employment or Leadership Position - Morphotek
Benjamin M Schwartz
No relevant relationships to disclose
Jacob Michael Estes
No relevant relationships to disclose
Ronald David Alvarez
Consultant or Advisory Role - Morphotek
Research Funding - Morphotek